Scientific Research

Scientific Research

  1. A study using 4mg doses of synthetic THC found that subjects showed significant improvements in PTSD-associated insomnia, nightmares, other general symptoms and also chronic pain.
  2. A study of cancer patients using low, medium and high doses of a THC/CBD compound found greater pain relief from the lowest dose compared to the medium and high dose.
  3. A double-blind study found patients who used CBD reported a significant decrease in anxiety. Researchers validated patients’ report by performing brain scans showing cerebral blood flow patterns consistent with anti-anxiety effect.
  4. Administration of CBD reduces resting blood pressure.
  5. Forty-three percent of patients who used CBD had at least a 50 percent reduction in convulsive-seizure frequency.
  6. Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease.
  7. Results support that CBD has potential in reducing damage caused by autoimmune/inflammatory diseases like multiple sclerosis.
  8. Researchers have found that THC might be slowing the process of mental decline that up to 50 percent of HIV patients experience.
  9. CBD has shown promise in a clinical trial as a possible treatment for psychosis. Patients who were treated with CBD had lower levels of psychotic symptoms such as paranoia and hallucinations.
  10. A study found that neither heavy nor occasional cannabis use is associated with decreased motivation.
  11. Colorado has seen a decrease in opioid related deaths since cannabis legalization. The reduction represents a reversal of the upward trend in opioid-related deaths in the state. Published 11/11/17.
  12. A study found that regular users of cannabis can greatly reduce their tolerance with a two-day break from cannabis use. Published 1/1/16.
  13. CBD was found to significantly reduced social anxiety measured through public speaking tests. Published 2/9/11.
  14. A double-blind study showed that participants experienced a decrease in anxiety after consuming CBD, and CBD demonstrated anti-anxiety effects on the brain. Published 9/10/10.
  15. Cannabis sativa and THC had beneficial influences on the symptoms of Tourette’s Syndrome including a significant reduction of motor and vocal tics and obsessive-compulsive disorder. 4/2002
  16. A synthetic cannabinoid showed to be promising in treating PTSD related insomnia and nightmares as well as managing chronic pain.
  17. Study finds that cannabis in addition to opioid pain killers decreases pain without altering plasma opioid levels, possibly allowing for opioid treatment at lower doses. 11/2/11
  18. The frequency of migraine headaches were decreased with medical cannabis use and helped abort acute migraines. 1/9/16
  19. Cannabinoids provided significant reduction in PTSD-related nightmares. 11/8/14
  20. High concentrations of THC were significantly associated with shorter sleep latency, less difficulty falling asleep and more daytime sleep. 8/15/15
  21. A review of medical cannabis studies finds it useful for cancer/chemo symptoms. 12/10/14
  22. 2017 Journal of Pharmaceutical and Biomedical Analysis – Cannabinoid Testing
  23. Study finds that patients with Tourette’s Syndrome experienced clinically significant symptom relief such as a decreased tic severity.
  24. Oral CBD administration is associated with reducing resting blood pressure and reducing blood pressure increases caused by stress.
  25. Daily administration of cannabinoids has been associated with a reduction in headache frequency.
  26. Inhaled medical cannabis reduced neuropathic pain in patients with spinal cord injuries. June 7, 2016
  27. Medical cannabis use reduced the stretch reflex in patients with multiple sclerosis. July 31, 2016
  28. A moderate relationship between THC concentrations in blood and the reduction of pain. August 31, 2016
  29. Cannabidiol (CBD) was shown to be effective in the treatment of epilepsy due to Tuberous sclerosis complex. October 3, 2016
  30. Clinical Endocannabinoid Deficiency Reconsidered. Published January 1, 2016
  31. Cannabinoids in Parkinson’s Disease. Published February 1, 2017
  32. The clinical Significance of Endocannabinoids in Endometriosis Pain Management. Published February 1, 2017
  33. Results showed the use of cannabis was associated with beneficial effects on some of fibromyalgia patients. Published 4/21/2011.
  34. Scientific review of the effects of vaporizing using commercially available vaporizers. (Volcano Medic, Arizer Solo, DaVinci Vaporizer). Published 1/19/2016.
  35. Conclusion links lipid-derived and endocannabinoid signaling as potential biological pathways involved in trauma associated pathophysiology. Published 2/8/2015.
  36. Study found patients reported moderate improvements in sleep disturbances, decreased symptoms of depression, attenuated impulsivity, and positive changes in some aspects of quality of life. They saw a decrease in other pharmaceutical use with opiates declining more than 42%. Published 10/13/2016.
  37. Scientist find transcripts associated with terpene biosynthesis. Published 3/29/2017.
  38. Effect of Intrapulmonary Tetrahydrocannabinol Administration in Humans. Zuurman et.al. 2008.
  39. Conversion of Cannabidiol to THC and Related Cannabinoids in Artificial Gastric Juice, and their Pharmacological Effects in Mice. Watanabe et.al. 2007.
  40. Smoked Cannabis For Chronic Neuropathic Pain: A Randomized Controlled Trail. Ware. 2010.
  41. Cannabis Smoke Condensate II: Influence of Tobacco on Tetrahydrocannabinol Levels. Van der Kooy et.al. 2008.
  42. History of Cannabis and Its Preparations in Saga, Science, and Sobriquet. Russo. 2007.
  43. Cannabinoids in the Management of Difficult to Treat Pain. Russo. 2006.
  44. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2. Pertwee et.al. 2010.
  45. The Management of Cancer Pain. Paice & Ferrell. 2011.
  46. Genetics and Marker-Assisted Selection of the Chemotype in Cannabis sativa L. Pacifico et.al. 2006.
  47. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pacher et.al. 2006.
  48. Development of a Rational Scale to Assess the Harm of Drugs of Potential Misuse. Nutt et.al. 2007.
  49. Non-Psychotropic Plant Cannabinoids: New Therapeutic Opportunities from an Ancient Herb. Mechoulam et. al. 2009.
  50. The Endocannabinoid System: An Osteopathic Perspective. McPartland. 2008.
  51. Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? McPartland & Russo. 2001.
  52. Potential of Marker-Assisted Selection in Hemp Genetic Improvement. Mandolino & Carboni. 2004.
  53. The New England Journal of Medicine: Medical Marijuana and the Law. Hoffman. 2010.
  54. Review on Clinical Studies with Cannabis and Cannabinoids 2005-2009. Hazekamp. 2010.
  55. An Evaluation of the Quality of Medicinal Grade Cannabis in the Netherlands. Hazekamp. 2006.
  56. Pharmokinetics and Pharmodynamics of Cannabinoids. Groternhermen. 2003.
  57. Cannabinoid Receptor 1 Binding Activity and Quantitative Analysis of Cannabis sativa L. Smoke and Vapor. Fischedick et.al. 2010.
  58. Potency Trends of THC and Other Cannabinoids in Confiscated Cannabis Preparations from 1993 to 2008. Elsohly. 2010.
  59. Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial. Ellis et.al. 2008.
  60. Endocannabinoids: Endogenous Cannabinoid Receptor Ligands with Neuromodulatory Action. Di Marzo et.al. 1998.
  61. The Inheritance of Chemical Phenotype in Cannabis sativa L (IV): Cannabinoid-Free Plants. de Meijer et.al. 2009.
  62. The Inheritance of Chemical Phenotype in Cannabis sativa L (III): Variation in Cannabichromene. de Meijer et. al. 2009.
  63. The Inheritance of Chemical Phenotype in Cannabis sativa L. (II): Cannabigerol Predominant Plants. de Meijer & Hammond. 2005.
  64. The Inheritance of Chemical Phenotype in Cannabis sativa L. de Meijer et.al. 2003.
  65. The Endocannabinoid System in Targeting Inflammatory Neurodegenerative Diseases. Centonze et.al. 2007.
  66. Cannabinoids in Medicine: A Review of Their Therapeutic Potential. Ben Amar. 2006.
  67. Cannabis in Painful HIV-Associated Sensory Neuropathy: A Randomized Placebo-Controlled Trial. Abrams et.al. 2007.
  68. Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection. Abrams et.al. 2003.


Patient, Physician and Caregiver New Jersey Medicinal Marijuana Program Information and Checklists

A variety of medical cannabis products now available

Curaleaf offers a range of safe, legal cannabis products.

Have Questions?

A Curaleaf expert is happy to help.